Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026-11 · 24 (11) · 1566-1573
DOI: 10.1111/ddg.70048 ↗Kurz gefasst
Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 25.03.2026. Verfasst von Andrea Roggo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Zurich, University of Zurich, Switzerland. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Melanoma, Pruritus, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI. Patients and methods Clinical data from 461 melanoma patients at the University Hospital of Zurich were analyzed in a retrospective, monocentric study. Patients received ICI either as combination therapy (ipilimumab and nivolumab) or monotherapy (nivolumab or pembrolizumab).
Results
Immune‐related pruritus (irPruritus) was associated with increased overall survival. It affected 23.0 % of patients (106/461), with a significantly higher frequency and earlier onset observed in combination therapy compared to monotherapy ( p < 0.001). A significant, pronounced increase in eosinophil counts was noted from baseline to onset of irPruritus. Topical steroids proved effective in 90.9 % of cases. Additionally, irPruritus was significantly correlated with both irFatigue ( p < 0.01) and irRash ( p < 0.001).
Conclusions
Pruritus is a common side effect of ICI therapy. Its correlation with irFatigue and irRash highlights the broader systemic impact impairing patients’ quality of life. Further prospective studies are needed to elucidate the underlying mechanisms such as involvement of eosinophils and identify optimal treatment strategies while maintaining ICI effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Zurich, University of Zurich, Switzerland.
- Department of Dermatology, Kantonsspital Aarau, Aarau, Switzerland.
ORCID-Profile: Andrea Roggo, Lukas Kraehenbuehl, Barbara Meier-Schiesser
Zitieren
APA
Roggo, A., Ivanovic, N., Turko, P., Kraehenbuehl, L., Levesque, M., Dummer, R., & Meier-Schiesser, B. (2026). Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 24(11), 1566-1573. https://doi.org/10.1111/ddg.70048
Vancouver
Roggo A, Ivanovic N, Turko P, Kraehenbuehl L, Levesque M, Dummer R, et al. Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026;24(11):1566-1573. doi:10.1111/ddg.70048
BibTeX
@article{Roggo2026,
author = {Roggo, Andrea and Ivanovic, Nikolina and Turko, Patrick and Kraehenbuehl, Lukas and Levesque, Mitchell and Dummer, Reinhard and Meier-Schiesser, Barbara},
title = {Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2026},
volume = {24},
number = {11},
pages = {1566--1573},
doi = {10.1111/ddg.70048}
}
EUVIMED